ORCHID PHARMA Financial Statement Analysis
|
||
|
The Revenues of ORCHID PHARMA have increased by 19.00% YoY .
The Earnings Per Share (EPS) of ORCHID PHARMA has increased by 60.09 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ORCHID PHARMA Last 5 Annual Financial Results
[BOM: 524372|NSE : ORCHPHARMA]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹666 Cr | ₹560 Cr | ₹450 Cr | ₹484 Cr | ₹600 Cr |
| Expenses | ₹582 Cr | ₹505 Cr | ₹399 Cr | ₹454 Cr | ₹612 Cr |
| Operating Profit (Excl OI) | ₹84 Cr | ₹55 Cr | ₹51 Cr | ₹30 Cr | ₹-12 Cr |
| Other Income | ₹19 Cr | ₹9.00 Cr | ₹15 Cr | ₹24 Cr | ₹17 Cr |
| Interest | ₹33 Cr | ₹33 Cr | ₹52 Cr | ₹6.23 Cr | ₹6.69 Cr |
| Depreciation | ₹55 Cr | ₹87 Cr | ₹109 Cr | ₹118 Cr | ₹130 Cr |
| Profit Before Tax | ₹55 Cr | ₹-57 Cr | ₹-95 Cr | ₹-70 Cr | ₹69 Cr |
| Profit After Tax | ₹55 Cr | ₹-57 Cr | ₹-95 Cr | ₹-70 Cr | ₹69 Cr |
| Consolidated Net Profit | ₹46 Cr | ₹-1.95 Cr | ₹-117 Cr | ₹-131 Cr | ₹69 Cr |
| Earnings Per Share (Rs) | ₹18.17 | ₹11.35 | ₹-0.48 | ₹-28.55 | ₹-32.11 |
| PAT Margin (%) | 11.60 | 8.30 | -10.17 | -21.16 | -14.41 |
| ROE(%) | 10.23 | 8.27 | -8.75 | -13.43 | -225.00 |
| ROCE(%) | 9.35 | 9.11 | -2.32 | -3.53 | -3.29 |
| Total Debt/Equity(x) | 0.12 | 0.48 | 0.41 | 0.69 | 0.74 |
Key Financials |
||
| Market Cap | : | ₹ 4,159.7 Cr |
| Revenue (TTM) | : | ₹ 901.6 Cr |
| Net Profit(TTM) | : | ₹ 110.1 Cr |
| EPS (TTM) | : | ₹ 21.7 |
| P/E (TTM) | : | 37.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ORCHID PHARMA | -2.7% | 5.6% | -26.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | 5.7% | 20.2% |
| DIVIS LABORATORIES | 1.7% | 6.2% | 52.9% |
| CIPLA | -0.7% | 7% | 8.4% |
| TORRENT PHARMACEUTICALS | -1.6% | 1.5% | 21.1% |
| DR REDDYS LABORATORIES | -2.3% | 2.5% | -6% |
| MANKIND PHARMA | -5.6% | -0.3% | -0.1% |
| ZYDUS LIFESCIENCES | 0.7% | 0.7% | -8.1% |
| LUPIN | -1% | 3% | 25.7% |
ORCHID PHARMA Revenues
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 19.00 % |
| 5 Yr CAGR | 2.64 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹666 Cr | 19.00 | |
| Mar2023 | ₹560 Cr | 24.33 | |
| Mar2022 | ₹450 Cr | -6.97 | |
| Mar2021 | ₹484 Cr | -19.36 | |
| Mar2020 | ₹600 Cr | - | |
ORCHID PHARMA Operating Profit
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 54.45 % |
| 5 Yr CAGR | Positive |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹84 Cr | 54.45 | |
| Mar2023 | ₹55 Cr | 7.73 | |
| Mar2022 | ₹51 Cr | 67.82 | |
| Mar2021 | ₹30 Cr | Positive | |
| Mar2020 | ₹-12 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 29.85 % |
| 5 Yr CAGR | Positive |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 12.66% | 29.85 | |
| Mar2023 | 9.75% | -13.41 | |
| Mar2022 | 11.26% | 80.45 | |
| Mar2021 | 6.24% | Positive | |
| Mar2020 | -1.97% | - | |
ORCHID PHARMA Profit After Tax
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | Positive |
| 5 Yr CAGR | -9.62 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹46 Cr | Positive | |
| Mar2023 | ₹-1.95 Cr | Negative | |
| Mar2022 | ₹-117 Cr | Negative | |
| Mar2021 | ₹-131 Cr | Negative | |
| Mar2020 | ₹69 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 39.76 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 11.6 % | 39.76 | |
| Mar2023 | 8.3 % | Positive | |
| Mar2022 | -10.17 % | Negative | |
| Mar2021 | -21.16 % | Negative | |
| Mar2020 | -14.41 % | - | |
ORCHID PHARMA Earnings Per Share (EPS)
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 60.09 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹18 | 60.09 | |
| Mar2023 | ₹11 | Positive | |
| Mar2022 | ₹-0.48 | Negative | |
| Mar2021 | ₹-29 | Negative | |
| Mar2020 | ₹-32 | - | |
ORCHID PHARMA Return on Capital Employed (ROCE)
[BOM: 524372|NSE : ORCHPHARMA]
| Y-o-Y | 2.63 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 9.35% | 2.63 | |
| Mar2023 | 9.11% | Positive | |
| Mar2022 | -2.32% | Negative | |
| Mar2021 | -3.53% | Negative | |
| Mar2020 | -3.29% | - | |
ORCHID PHARMA Share Price vs Sensex
| Current Share Price | : | ₹820.5 |
| Current MarketCap | : | ₹ 4,159.7 Cr |
| Updated EOD on | : | May 05,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ORCHID PHARMA | -2.7% |
5.6% |
-26.9% |
| SENSEX | 2% |
4.1% |
9.6% |
ORCHID PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 1.2% | 2.2% | 19.6% |
| BSE SMALLCAP | -0.1% | 2.5% | 1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 1.5% | 3.6% | 6.3% |
| NIFTY MICROCAP 250 | -1% | 1.7% | 2% |
You may also like the below Video Courses
FAQ about ORCHID PHARMA Financials
How the annual revenues of ORCHID PHARMA have changed ?
The Revenues of ORCHID PHARMA have increased by 19.00% YoY .
How the Earnings per Share (EPS) of ORCHID PHARMA have changed?
The Earnings Per Share (EPS) of ORCHID PHARMA has increased by 60.09 % YoY .
Check out Intrinsic Value of Peers of ORCHID PHARMA
Compare Stock Analytics of Peers of ORCHID PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
